TRIUS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Trius Ther...
31 Julho 2013 - 10:54PM
Business Wire
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
and the law firm of Kahn Swick & Foti, LLC (“KSF”) announce
that KSF has commenced an investigation into the Board of Directors
of Trius Therapeutics, Inc. (“Trius” or the “Company”) (NASDAQ GM:
TSRX) in connection with their conduct related to the sale of the
Company to Cubist Pharmaceuticals, Inc. (NASDAQ GS: CBST). Under
the terms of the proposed transaction, shareholders of Trius will
receive $13.50 in cash for each share of Trius common stock that
they own. In addition, each Trius shareholder will receive one
contingent value right entitling the holder to receive an
additional cash payment of up to $2.00 for each share that they own
if certain commercial sales milestones are achieved.
KSF’s investigation is focusing on whether Trius and/or its
officers and directors secured sufficient value for the
shareholders of the Company, violated their fiduciary duties,
and/or violated state or federal securities laws.
If you have information that would assist KSF in its
investigation, or would like to discuss your legal rights, you may,
without obligation or cost to you, e-mail or call KSF Managing
Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) or attorney
Michael Palestina (michael.palestina@ksfcounsel.com) toll free at
855-768-1857 or via cell phone any time at 504-236-7315.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney
General Charles C. Foti, Jr., is a law firm focused on
transactional litigation, as well as securities class action and
shareholder derivative litigation. With offices in New York and
Louisiana, KSF's lawyers have significant experience litigating
complex securities class actions nationwide on behalf of both
institutional and individual shareholders.
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLCMichael Palestina, Esq.,
855-768-1857Cell: 504-236-7315michael.palestina@ksfcounsel.com
Trius Therapeutics, Inc. (MM) (NASDAQ:TSRX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Trius Therapeutics, Inc. (MM) (NASDAQ:TSRX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Trius Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Kahn Swick & Foti, LLC